Abstract
Correction to “Roy S, Dhaneshwar S. Role of prebiotics, probiotics, and synbiotics in management of inflammatory bowel disease: Current perspectives. World J Gastroenterol 2023; 29: 2078-2100 [PMID: 37122604 DOI: 10.3748/wjg.v29.i14.2078]”. In this article, a correction note is to be added.
Keywords: Ulcerative colitis, Crohn’s disease, Pouchitis, Dysbiosis, Microbiota, Inflammation
Core Tip: This manuscript is to add a “correction note” to “Roy S, Dhaneshwar S. Role of prebiotics, probiotics, and synbiotics in management of inflammatory bowel disease: Current perspectives. World J Gastroenterol 2023; 29: 2078-2100 [PMID: 37122604 DOI: 10.3748/wjg.v29.i14.2078]”.
TO THE EDITOR
Correction to: Roy S, Dhaneshwar S. Role of prebiotics, probiotics, and synbiotics in management of inflammatory bowel disease: Current perspectives. World J Gastroenterol 2023; 29(14): 2078-2100.
In this article, a correction note is to be added[1]. The corresponding author received a mail from Dr. Claudio De Simone sharing his concern about a probiotic formulation VSL#3 which is mentioned in this review article. Dr. Claudio wishes us to publish a corrigendum. It is an earnest request that please incorporate the following correction note and publish a corrigendum regarding the same.
Correction note: This review article includes references to several studies that investigated a probiotic formulation formerly marketed as VSL#3 which is currently, generically referred to as the “De Simone Formulation”. It is important to note that the current product marketed as VSL#3 differs from the De Simone Formulation as also stated by the federal court of Maryland in the Civil Action, No. TDC-15-1356. They are distinct probiotic formulations with different compositions and characteristics. Currently, the De Simone Formulation is accessible under Vivomixx (in Europe) and Visbiome (in the United States) brand names.
Footnotes
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Provenance and peer review: Invited article; Externally peer reviewed.
Peer-review model: Single blind
Peer-review started: August 16, 2023
First decision: August 25, 2023
Article in press: September 1, 2023
Specialty type: Gastroenterology and hepatology
Country/Territory of origin: India
Peer-review report’s scientific quality classification
Grade A (Excellent): A, A
Grade B (Very good): 0
Grade C (Good): 0
Grade D (Fair): 0
Grade E (Poor): 0
P-Reviewer: Salvadori M, Italy; Zhu L, China S-Editor: Fan JR L-Editor: A P-Editor: Fan JR
Contributor Information
Supriya Roy, Department of Pharmacology, Amity Institute of Pharmacy, Lucknow, Amity University Uttar Pradesh, Noida 201303, Uttar Pradesh, India.
Suneela Dhaneshwar, Department of Pharmaceutical Chemistry, Amity Institute of Pharmacy, Amity University Maharashtra, Mumbai 410206, Maharashtra, India. suneeladhaneshwar@rediffmail.com.
References
- 1.Roy S, Dhaneshwar S. Role of prebiotics, probiotics, and synbiotics in management of inflammatory bowel disease: Current perspectives. World J Gastroenterol. 2023;29:2078–2100. doi: 10.3748/wjg.v29.i14.2078. [DOI] [PMC free article] [PubMed] [Google Scholar]